Skip to main content
Atrás
AMPH logo

Amphastar Pharmaceuticals, Inc.

Calidad de datos: 100%
AMPH
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$19.57
▲ $0.34 (1.77%)
Cap. Mercado: 899.28M
Rango del Día
$19.39 $19.96
Rango de 52 Semanas
$17.03 $31.26
Volumen
296,535
Promedio 50D / 200D
$24.98 / $25.55
Cierre Anterior
$19.23

Quick Summary

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (631 pares)

Métrica Acción Mediana del Sector
P/E 9.2 0.2
P/B 1.1 3.0
ROE % 12.9 3.6
Net Margin % 13.6 3.8
Rev Growth 5Y % 13.2 9.9
D/E 0.8 0.2

Precio Objetivo de Analistas

Hold
$30.00 +53.3%
P/E Futuro
5.96
EPS Futuro
$3.28
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
756.52M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $3.00
$2.92 – $3.07
 905.00M 1
FY2029 $3.02
$2.94 – $3.09
 881.00M 1
FY2028 $3.62
$3.52 – $3.70
 824.16M 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-26 $0.90 $0.73 -19.2%
2025-11-06 $0.77 $0.93 +20.8%
2025-08-07 $0.71 $0.85 +19.7%
2025-05-07 $0.66 $0.74 +12.1%
2025-02-27 $1.01 $0.92 -8.9%
2024-11-06 $0.99 $0.96 -3.0%
2024-08-07 $0.77 $0.94 +22.1%
2024-05-08 $0.96 $1.04 +8.3%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

Ex-Date Payment Date Amount Yield
Jun 11, 2010 Jun 30, 2010 $0.30 3.43%
Jun 11, 2009 Jun 30, 2009 $0.30 3.43%

Puntos Clave

Revenue grew 13.24% annually over 5 years — strong growth
Earnings declined -38.51% over the past year
ROE of 12.90% — decent returns on equity
Generating 121.23M in free cash flow
P/E of 9.17 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 14.89%

Crecimiento

Revenue Growth (5Y)
13.24%
Revenue (1Y)-1.65%
Earnings (1Y)-38.51%
FCF Growth (3Y)-8.67%

Calidad

Return on Equity
12.90%
ROIC7.29%
Net Margin13.63%
Op. Margin19.50%

Seguridad

Debt / Equity
0.83
Current Ratio4.02
Interest Coverage5.51

Valoración

P/E Ratio
9.17
Forward P/E5.96
P/B Ratio1.14
EV/EBITDA9.87
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -1.65% Revenue Growth (3Y) 5.70%
Earnings Growth (1Y) -38.51% Earnings Growth (3Y) -15.55%
Revenue Growth (5Y) 13.24% Earnings Growth (5Y) 12.10%
Profitability
Revenue (TTM) 719.89M Net Income (TTM) 98.09M
ROE 12.90% ROA 6.02%
Gross Margin 49.46% Operating Margin 19.50%
Net Margin 13.63% Free Cash Flow (TTM) 121.23M
ROIC 7.29% FCF Growth (3Y) -8.67%
Safety
Debt / Equity 0.83 Current Ratio 4.02
Interest Coverage 5.51
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 9.17 Forward P/E 5.96
P/B Ratio 1.14 P/S Ratio 1.25
PEG Ratio -0.35 Forward PEG N/A
EV/EBITDA 9.87 Fwd EV/EBITDA 8.75
Forward P/S 1.19 Fwd Earnings Yield 16.78%
FCF Yield 13.48%
Market Cap 899.28M Enterprise Value 1.39B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 719.89M 731.97M 644.40M 498.99M 437.77M
Net Income 98.09M 159.52M 137.55M 91.39M 62.12M
EPS (Diluted) 2.03 3.06 2.60 1.74 1.25
Gross Profit 356.06M 373.86M 351.12M 248.86M 199.74M
Operating Income 140.40M 205.42M 196.99M 107.50M 69.89M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.63B 1.58B 1.51B 741.99M 671.53M
Total Liabilities 840.49M 845.17M 873.49M 213.33M 226.01M
Shareholders' Equity 788.81M 732.30M 639.42M 528.66M 445.52M
Total Debt 656.00M 650.55M 623.64M 102.58M 104.66M
Cash & Equivalents 170.18M 151.61M 144.30M 156.10M 126.35M
Current Assets 636.02M 534.07M 489.60M 378.32M 318.12M
Current Liabilities 158.16M 173.76M 225.41M 94.86M 103.81M